Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...

"We will continue our close collaboration with the Parkinson's community as we further evaluate the data to determine next steps." Alpha-synuclein is a protein that tends to get misfolded and ...

Over time, the disease can also affect memory and lead to dementia. A similar condition called Lewy Body Dementia (LBD), ...

The assay for a particular abnormal form of the protein alpha-synuclein – known as αSyn-SAA – could also be used to diagnose people with Parkinson’s more quickly, help identify the best ...

The B vitamin mitigates manganese neurotoxicity, which produces symptoms that resemble Parkinson's disease. The vitamin improves dopamine production in the brain and offers potential therapeutic ...

U.S. Department of Defense awards $4 million to researchers at OHSU, University of Washington, VA Portland, VA Puget Sound to ...

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...

Mitochondria are critical for cellular homeostasis, regulating bioenergetics, redox balance, Ca2+ signaling, and cell death.

Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...

Jan. 14, 2025 — There may be a link between hearing impairment and an increased risk of developing Parkinson's according to new research. This is one of the first studies to examine whether ...